Gian Life Care Intrinsic Value
Gian Life Care intrinsic value. Gian Life Care (GIANLIFE) median intrinsic value is ₹9.28 from 3 valuation models (range ₹3–₹11), vs current price ₹4.35 — +113.3% upside (Trading Below Calculated Value), margin of safety 53.1%. For current market price and key ratios, visit GIANLIFE share price screener.
GIANLIFE Valuation Methods Summary — DCF, Graham Number & P/E
Gian Life Care intrinsic value across 3 models vs current price ₹4.35 — upside/downside and value range per method. Compare with GIANLIFE fair price to assess whether the stock is under or overvalued.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| Book Value Method | asset | ₹10.88 | ₹9.79 - ₹11.97 | +150.1% | Book Value/Share: ₹19.00, P/B: 1.0x |
| Revenue Multiple Method | revenue | ₹3.20 | ₹2.88 - ₹3.52 | -26.4% | Revenue/Share: ₹4.00, P/S: 0.8x |
| Simple DCF (5Y) | dcf | ₹9.28 | ₹7.42 - ₹11.14 | +113.3% | CF Growth: 5.0%, Discount: 15% |
GIANLIFE Intrinsic Value vs Market Price — All Valuation Models
Gian Life Care fair value range ₹3–₹11 vs current market price ₹4.35 across 3 valuation models. Read GIANLIFE dividend yield for the complete payout history and dividend yield track record.
GIANLIFE Intrinsic Value Analysis — Undervalued or Overvalued?
Gian Life Care median intrinsic value ₹9.28, current price ₹4.35 — Trading Below Calculated Value by 113.3%, margin of safety 53.1%.
What is the intrinsic value of GIANLIFE?
Based on our comprehensive analysis using 3 different valuation methods, the estimated intrinsic value of Gian Life Care (GIANLIFE) is ₹9.28 (median value). With the current market price of ₹4.35, this represents a +113.3% variance from our estimated fair value.
The valuation range spans from ₹3.20 to ₹10.88, indicating ₹3.20 - ₹10.88.
Is GIANLIFE undervalued or overvalued?
Based on our multi-method analysis, Gian Life Care (GIANLIFE) appears to be trading below calculated value by approximately 113.3%.
GIANLIFE Financial Health — Key Ratios vs Industry Benchmarks
Gian Life Care financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Return on Equity | -21.1% | Industry Standard: 15%+ | Below 10% | Measures shareholder return efficiency |
| Operating Margin | -62.0% | Industry Standard: 20%+ | Below 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.11x | Industry Standard: 1.0x+ | Below 0.5x | Measures asset utilization efficiency |
GIANLIFE Cash Flow Quality — Operating & Free Cash Flow
Gian Life Care operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹0 Cr | ₹0 Cr | Negative Cash Flow | 3/10 |
| March 2024 | ₹1 Cr | ₹1 Cr | Positive Free Cash Flow | 8/10 |
| March 2023 | ₹2 Cr | ₹2 Cr | Positive Free Cash Flow | 8/10 |
| March 2022 | ₹6 Cr | ₹4 Cr | Positive Free Cash Flow | 8/10 |